Tsenova, L., Mangaliso, B., Muller, G., Chen, Y., Freed- man, V.H., Stirling, D., et al. (2002) Use of IMDi3, a tha- lidomide analog, as an adjunct to therapy for experiment- tal tuberculous meningitis. Antimicrobial Agents and Chemo- therapy, 46, 1887-1895. doi:10.1128/AAC.46.6.1887-1895.2002

has been cited by the following article:

• TITLE: New antimyeloma drugs in spinal cord infiltration for multiple myeloma. Determination of lenalidomide in cerebrospinal fluid with ultrasensitive high-performance liquid chromatography

  AUTHORS: Inmaculada Rapado, Juan José Lahuerta, Laura Montejano, María Ángeles Montalbán, Laura Pares, Joaquín Martínez- López

  KEYWORDS: Lenalidomide; Multiple Myeloma; Spinal Cord Infiltration; High-Performance Liquid Chromatography

  JOURNAL NAME: Modern Chemotherapy, Vol.1 No.2, October 15, 2012

  ABSTRACT: A 64-year-old woman with IgA kappa multiple myeloma was treated with thalidomide-dexa- methasone. Due to progression of the disease, bortezomib, doxorubicin and dexamethasone were administered, followed by autologous stem cell transplantation. Although near-complete remission was achieved, 5 months later, neuro- logical symptoms appeared and the patient was diagnosed with multiple myeloma with cells in- filtrating the spinal cord. Bis-chloronitrosourea, bortezomib and lenalidomide were then admin- istered and although the patient remained neu- rologically asymptomatic, she died 3 months later becausee of disease progression. Lena- lidomide entered into the cerebrospinal fluid (confirmed by ultrasensitive high-performance liquid chromatography), although did not im- prove the poor prognosis of multiple myeloma involving the central nervous system.